Liver-specific mitochondrial amidoxime-reducing component 1 (Mtarc1) knockdown protects the liver from diet-induced MASH in multiple mouse models.

Autor: Guo Y; Research Biomarkers, Amgen Research, South San Francisco, California, USA., Gao Z; Cardiometabolic Disorders, Amgen Research, South San Francisco, California, USA., LaGory EL; Pharmacokinetics and Drug Metabolism, Amgen Research, South San Francisco, California, USA., Kristin LW; Translational Safety and Bioanalytical Sciences, Amgen Research, South San Francisco, California, USA., Gupte J; Cardiometabolic Disorders, Amgen Research, South San Francisco, California, USA., Gong Y; Cardiometabolic Disorders, Amgen Research, South San Francisco, California, USA., Rardin MJ; Discovery Technology Platforms, Amgen Research, South San Francisco, California, USA., Liu T; Center for Research Acceleration by Digital Innovation, Amgen Research, Cambridge, Massachusetts, USA., Nguyen TT; Center for Research Acceleration by Digital Innovation, Amgen Research, Cambridge, Massachusetts, USA., Long J; RNA Therapeutics, Amgen Research, One Amgen Center Drive, Thousand Oaks, California, USA., Hsu YH; Center for Research Acceleration by Digital Innovation, Amgen Research, Cambridge, Massachusetts, USA., Murray JK; RNA Therapeutics, Amgen Research, One Amgen Center Drive, Thousand Oaks, California, USA., Lade J; Pharmacokinetics and Drug Metabolism, Amgen Research, South San Francisco, California, USA., Jackson S; Cardiometabolic Disorders, Amgen Research, South San Francisco, California, USA., Zhang J; Cardiometabolic Disorders, Amgen Research, South San Francisco, California, USA.

Publikováno v: Hepatology communications [Hepatol Commun] 2024 May 02; Vol. 8 (5). Date of Electronic Publication: 2024 May 02 (Print Publication: 2024).